Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP

Journal of Infectious Diseases

Volumn 209, Issue 5, 2014, Pages 703-710

  Boltz, Valerie F ^a   Bao, Yajing ^b   Lockman, Shahin ^c   Halvas, Elias K ^d   Kearney, Mary F ^a   McIntyre, James A ^e,f   Schooley, Robert T ^g   Hughes, Michael D ^b   Coffin, John M ^h   Mellors, John W ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e ANOVA HEALTH INSTITUTE   (South Africa)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antiretroviral therapy failure; minor drug resistant variants; single dose nevirapine

Indexed keywords

ANTIRETROVIRAL THERAPY FAILURE; MINOR DRUG-RESISTANT VARIANTS; SINGLE-DOSE NEVIRAPINE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; NEVIRAPINE; TREATMENT FAILURE;

EID: 84894259565     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit635     Document Type: Conference Paper

References (35)

1. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267:483-9.
2. Kearney M, Palmer S, Maldarelli F, et al. Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS 2008; 22:497-501.
3. Gianella S, Richman DD. Minority variants of drug-resistant HIV. J Infect Dis 2010; 202:657-66.
4. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68:1660-6.
5. Mayers DL, Japour AJ, Arduino JM, et al. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group. Antimicrob Agents Chemother 1994; 38:307-14.
6. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005; 192:16-23.
7. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapineresistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA 2006; 103:7094-9.
8. Korn K, Reil H, Walter H, Schmidt B. Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results. J Clin Microbiol 2003; 41:3559-65.
9. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-85.
10. Johnson VA, Calvez V, Gunthard HF, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antiviral Medicine 2011; 19:156-64.
11. Lockman S, Hughes MD, McIntyre J, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 2010; 363:1499-509.
12. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008; 5:e158.
13. Halvas EK, Wiegand A, Boltz VF, et al. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients. J Infect Dis 2010; 201:672-80.
14. Paredes R, Lalama CM, Ribaudo HJ, et al. Pre-existing minority drugresistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010; 201:662-71.
15. Li JZ, Paredes R, Ribaudo HJ, et al. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 2012; 26:185-92.
16. Jakobsen MR, Tolstrup M, Sogaard OS, et al. Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. Clin Infect Dis 2010; 50:566-73.
17. Metzner KJ, Rauch P, von Wyl V, et al. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis 2010; 201:1063-71.
18. Metzner KJ, Rauch P, Braun P, et al. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naive patients. J Clin Virol 2010; 50: 156-61.
19. Messiaen P, Verhofstede C, Vandenbroucke I, et al. Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTIbased regimen in treatment-naive patients. Virology 2012; 426:7-11.
20. Boltz VF, Zheng Y, Lockman S, et al. Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci USA 2011; 108:9202-7.
21. Lockman S, Hughes M, Sawe F, et al. Nevirapine-versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med 2012; 9:e1001236.
22. Palmer S, Boltz V, Maldarelli F, et al. Selection and persistence of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. Aids 2006; 20:701-10.
23. Boltz VF, Maldarelli F, Martinson N, et al. Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design. J Virol Methods 2010; 164:122-6.
24. Kwok S, Kellogg DE, McKinney N, et al. Effects of primerlate mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies. Nucleic Acids Res 1990; 18: 999-1005.
25. Cha RS, Zarbl H, Keohavong P, Thilly WG. Mismatch amplification mutation assay (MAMA): application to the c-H-ras gene. PCR Methods Appl 1992; 2:14-20.
26. Hance AJ, Lemiale V, Izopet J, et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 2001; 75:6410-7.
27. Halvas EK, Aldrovandi GM, Balfe P, et al. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol 2006; 44:2612-4.
28. Ambrose Z, Palmer S, Boltz VF, et al. Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol 2007; 81:12145-55.
29. Palmer S, Boltz VF, Chow JY, et al. Short-course Combivir after singledose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women. Antivir Ther 2011; 17:327-36.
30. Boltz VF, Ambrose Z, Kearney MF, et al. Ultrasensitive allele-specific PCR reveals rare preexisting drug resistant variants and a large replicating virus population in macaques infected with RT-SHIV. J Virol 2012; 86:12525-30.
31. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-47.
32. Jourdain G, Wagner TA, Ngo-Giang-Huong N, et al. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure. Clin Infect Dis 2010; 50:1397-404.
33. Lecossier D, Shulman NS, Morand-Joubert L, et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 2005; 38:37-42.
34. Svarovskaia ES, Margot NA, Bae AS, et al. Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. J Acquir Immune Defic Syndr 2007; 46: 174-80.
35. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011; 305:1327-35.